Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -3260.14% is 55% above its 2-year average of -7228.36%, near the high end of its 2-year range (-30468.42%–-2231.13%).
7.63% above its 12-month average of -3529.56%.
Reported quarterly EBITDA margin; no daily interpolation. Q1 FY2026 (2026-03-31): -2231.13%.
EBITDA MARGIN
-3260.14%
EBITDA MARGIN AVG TTM
-3529.56%
EBITDA MARGIN AVG 3Y
N/A
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+7.63%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Rallybio Corporation
Market Cap
$89.69M
EBITDA Margin
-3260.14%
TTM Avg
-3529.56%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$89.84M
EBITDA Margin
15.84%
TTM Avg
9.89%
3Y Avg
0.86%
5Y Avg
4.00%
Market Cap
$89.53M
EBITDA Margin
-35.83%
TTM Avg
-39.56%
3Y Avg
-111.97%
5Y Avg
-250.85%
Market Cap
$89.12M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$91.18M
EBITDA Margin
5.05%
TTM Avg
6.33%
3Y Avg
5.80%
5Y Avg
5.80%
Market Cap
$91.36M
EBITDA Margin
-19.79%
TTM Avg
-29.84%
3Y Avg
-150.95%
5Y Avg
-150.95%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rallybio Corporation (RLYB) | $89.69M | -3260.14% | -3529.56% | N/A | N/A |
| ImmuCell Corporation (ICCC)vs › | $89.84M | 15.84% | 9.89% | 0.86% | 4.00% |
| electroCore, Inc. (ECOR)vs › | $89.53M | -35.83% | -39.56% | -111.97% | -250.85% |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $89.86M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $89.45M | 23.63% | 23.21% | 8.97% | 9.09% |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $89.12M | N/A | N/A | N/A | N/A |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $91.18M | 5.05% | 6.33% | 5.80% | 5.80% |
| Equillium, Inc. (EQ)vs › | $91.36M | -19.79% | -29.84% | -150.95% | -150.95% |
| Biomea Fusion, Inc. (BMEA)vs › | $91.46M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $83.61M | 31.45% | -14.67% | -906.21% | -1050.55% |
Gross Margin
89.3%
EBITDA Margin
-3260.1%
Operating Margin
-3270.9%
Net Margin
7051.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-03-31 | -2231.13% |
| 2025-12-31 | -2886.94% |
| 2025-09-30 | -3250.00% |
| 2025-06-30 | -4731.60% |
| 2025-03-31 | -4548.11% |
| 2024-12-31 | -30468.42% |
| 2024-09-30 | -4024.75% |
| 2024-06-30 | -5685.95% |
